Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Surrozen Inc (SRZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SRZN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -81.82% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.89M USD | Price to earnings Ratio - | 1Y Target Price 38.5 |
Price to earnings Ratio - | 1Y Target Price 38.5 | ||
Volume (30-day avg) 12202 | Beta 0.74 | 52 Weeks Range 6.00 - 18.17 | Updated Date 04/1/2025 |
52 Weeks Range 6.00 - 18.17 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -18.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 12.32% |
Management Effectiveness
Return on Assets (TTM) -32.65% | Return on Equity (TTM) -173.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8736849 | Price to Sales(TTM) 3.79 |
Enterprise Value 8736849 | Price to Sales(TTM) 3.79 | ||
Enterprise Value to Revenue 0.87 | Enterprise Value to EBITDA 0.71 | Shares Outstanding 3249800 | Shares Floating 219491 |
Shares Outstanding 3249800 | Shares Floating 219491 | ||
Percent Insiders 1.67 | Percent Institutions 83.56 |
Analyst Ratings
Rating 5 | Target Price 45 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Surrozen Inc
Company Overview
History and Background
Surrozen, Inc. was founded in 2016 and is a biotechnology company that discovers and develops antibody-based therapeutics to selectively modulate Wnt signaling for tissue repair and regeneration. It went public via SPAC merger in 2021. The company has focused on developing therapies for liver and intestinal diseases.
Core Business Areas
- Liver Disease Therapeutics: Focuses on developing antibody therapeutics that target Wnt signaling to regenerate and repair damaged liver tissue in diseases like severe alcohol-associated hepatitis (sAH).
- Intestinal Disease Therapeutics: Develops therapeutics aimed at intestinal regeneration and repair, targeting conditions like inflammatory bowel disease (IBD).
- Discovery and Research: Continues to research and identify novel targets and develop platform technologies to further advance tissue regeneration.
Leadership and Structure
Surrozen has a board of directors and an executive leadership team responsible for strategic direction and operational execution. The CEO leads the management team, overseeing research, development, and business operations.
Top Products and Market Share
Key Offerings
- SZN-1326 (Liver): An antibody targeting FZD5 for liver regeneration. Currently in clinical development for severe alcohol-associated hepatitis (sAH). Market share is not yet applicable as it is still in clinical trials. Competitors include companies developing other therapies for sAH, such as Gilead Sciences and Genfit, although these don't necessarily target the same Wnt pathway.
- SZN-043 (Intestine): An antibody targeting R-spondin 3 for intestinal regeneration. Preclinical development focuses on inflammatory bowel disease (IBD). Market share is not applicable as it is still preclinical. Competitors developing IBD therapies include AbbVie (Humira, Rinvoq), Johnson & Johnson (Stelara), and Takeda (Entyvio).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D spending, long development timelines, and regulatory scrutiny. Regenerative medicine, particularly targeting Wnt signaling, is an area of growing interest.
Positioning
Surrozen is positioned as a company focused on Wnt signaling modulation for tissue regeneration, differentiating itself through its specific antibody-based approach. Its competitive advantage lies in its expertise in Wnt pathway biology and its proprietary antibody technology.
Total Addressable Market (TAM)
The combined TAM for liver diseases and IBD is significant, estimated to be in the tens of billions of dollars. Surrozen aims to capture a portion of this market by addressing unmet needs in regenerative therapies for these conditions. The specific TAM will depend on the success of their clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary antibody technology targeting Wnt signaling
- Expertise in tissue regeneration and Wnt pathway biology
- Potential to address unmet needs in liver and intestinal diseases
Weaknesses
- Limited cash runway
- Dependence on successful clinical trial outcomes
- Early-stage development pipeline
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new disease areas
- Positive clinical trial data leading to increased investor confidence
Threats
- Clinical trial failures
- Competition from other biotechnology and pharmaceutical companies
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- JNJ
- TAK
Competitive Landscape
Surrozen differentiates itself through its Wnt-signaling-targeted approach. It competes with companies developing other therapies for liver and intestinal diseases but has the potential to offer a regenerative solution.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is pre-revenue. Growth is measured by the progress of its pipeline and preclinical assets to clinical studies.
Future Projections: Future growth depends on the success of clinical trials for SZN-1326 and SZN-043. Analyst projections are based on estimates of potential market share and pricing if these therapies are approved.
Recent Initiatives: Recent initiatives include advancing SZN-1326 into clinical trials, ongoing preclinical development of SZN-043, and exploring potential partnerships.
Summary
Surrozen is an early-stage biotech company focused on innovative regenerative therapies. Its technology targeting the Wnt pathway for liver and intestinal diseases holds significant promise. However, the company faces typical biotech challenges, including cash constraints and clinical trial risks. Positive trial data and strategic partnerships are vital for Surrozen's success.
Similar Companies
- GILD
- ABBV
- JNJ
- TAK
Sources and Disclaimers
Data Sources:
- Surrozen Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-01-11 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 42 | Website https://www.surrozen.com |
Full time employees 42 | Website https://www.surrozen.com | ||
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.